331 reports of this reaction
1.8% of all BRENTUXIMAB VEDOTIN reports
#13 most reported adverse reaction
DISEASE PROGRESSION is the #13 most commonly reported adverse reaction for BRENTUXIMAB VEDOTIN, manufactured by SEAGEN INC.. There are 331 FDA adverse event reports linking BRENTUXIMAB VEDOTIN to DISEASE PROGRESSION. This represents approximately 1.8% of all 18,008 adverse event reports for this drug.
Patients taking BRENTUXIMAB VEDOTIN who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is a less commonly reported adverse event for BRENTUXIMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to disease progression, the following adverse reactions have been reported for BRENTUXIMAB VEDOTIN:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 331 FDA reports for BRENTUXIMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 1.8% of all adverse event reports for BRENTUXIMAB VEDOTIN, making it a notable side effect.
If you experience disease progression while taking BRENTUXIMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.